vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
Key Highlights
- ➤166 patients randomized as vTv completes Phase 3 CATT1 enrollment
- ➤Topline CATT1 results expected in mid 2027
- ➤Cadisegliatin targets clinically significant hypoglycemia reduction in Type 1 diabetes
- ➤FDA granted cadisegliatin Breakthrough Therapy designation
- ➤CATT1 compares 800 mg once-daily, twice-daily, and placebo arms
Expert Statements
Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics
“Completing enrollment for the CATT1 study is a significant milestone for vTv, and we’re deeply grateful to the study participants whose commitment made this possible.”
Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics
“Cadisegliatin has the potential to reduce the risk of hypoglycemia, which remains a significant unmet need for people living with T1D, and we look forward to completing the study and reporting topline results in mid 2027.”
Thomas Strack, MD, Chief Medical Officer of vTv Therapeutics
“This milestone is an important step forward for the cadisegliatin program.”
Thomas Strack, MD, Chief Medical Officer of vTv Therapeutics
“Our focus now is maintaining the quality and integrity of the study through completion and continuing the important work of advancing cadisegliatin development toward potential approval.”
HIGH POINT, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that the Company has completed enrollment of its Phase 3 Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (CATT1) study. A total of 166 patients have been randomized in the study evaluating cadisegliatin, a potential first-in-class oral, liver-selective glucokinase activator that has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to insulin for the treatment of T1D.
“Completing enrollment for the CATT1 study is a significant milestone for vTv, and we’re deeply grateful to the study participants whose commitment made this possible,” said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics. “Cadisegliatin has the potential to reduce the risk of hypoglycemia, which remains a significant unmet need for people living with T1D, and we look forward to completing the study and reporting topline results in mid 2027.”
Get started
Create a free account to read the full story.